Zevra Therapeutics (NASDAQ:ZVRA) Sets New 12-Month High – What’s Next?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA)’s stock price hit a new 52-week high on Tuesday . The stock traded as high as $14.30 and last traded at $14.2950, with a volume of 267986 shares traded. The stock had previously closed at $14.01.

Analyst Upgrades and Downgrades

ZVRA has been the subject of a number of recent research reports. BTIG Research restated a “buy” rating and issued a $27.00 target price (up from $23.00) on shares of Zevra Therapeutics in a research note on Tuesday, June 9th. Weiss Ratings lowered shares of Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a report on Friday, May 22nd. UBS Group reaffirmed a “buy” rating on shares of Zevra Therapeutics in a report on Wednesday, June 24th. Citizens Jmp upped their target price on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the company a “market outperform” rating in a research note on Tuesday, June 9th. Finally, Guggenheim upped their target price on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the company a “buy” rating in a research note on Wednesday, June 10th. Nine research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $29.29.

Zevra Therapeutics Trading Up 2.9%

The company’s fifty day moving average price is $11.41 and its two-hundred day moving average price is $9.85. The firm has a market cap of $852.44 million, a P/E ratio of 7.25 and a beta of 0.91.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.12. The firm had revenue of $36.22 million during the quarter, compared to the consensus estimate of $31.96 million. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%. On average, analysts predict that Zevra Therapeutics, Inc. will post 0.56 EPS for the current fiscal year.

Institutional Investors Weigh In On Zevra Therapeutics

A number of large investors have recently bought and sold shares of the business. Quantinno Capital Management LP increased its holdings in Zevra Therapeutics by 114.1% during the 1st quarter. Quantinno Capital Management LP now owns 32,022 shares of the company’s stock valued at $298,000 after purchasing an additional 17,065 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Zevra Therapeutics by 259.2% in the first quarter. Dimensional Fund Advisors LP now owns 554,802 shares of the company’s stock worth $5,168,000 after purchasing an additional 400,336 shares in the last quarter. AIGH Capital Management LLC acquired a new position in Zevra Therapeutics in the first quarter worth $11,184,000. Simplify Asset Management Inc. grew its holdings in shares of Zevra Therapeutics by 137.5% during the first quarter. Simplify Asset Management Inc. now owns 100,630 shares of the company’s stock worth $938,000 after purchasing an additional 58,265 shares during the last quarter. Finally, Janney Montgomery Scott LLC grew its holdings in shares of Zevra Therapeutics by 16.7% during the first quarter. Janney Montgomery Scott LLC now owns 236,834 shares of the company’s stock worth $2,207,000 after purchasing an additional 33,951 shares during the last quarter. 35.03% of the stock is currently owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.